Timeline: International Phase 3 Clinical Trial of Verdiperstat in Multiple System Atrophy

“Top line results from the study are expected to be available in 3Q2021 and will help to characterize the potential benefits and risks of Verdiperstat in MSA. After the study results are available, Biohaven will provide further updates on the development of Verdiperstat for the treatment of MSA.”

For information on the Mechanism of Action (MOA), please click below to access a video explaining Verdiperstat:

CLICK TO DOWNLOAD UPDATE FROM BIOHAVEN MAY 2021

CLICK BELOW TO VIEW VIDEO ON VERDIPERSTAT: